compass_positive_tagline-01.png
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
13 déc. 2021 07h00 HE | COMPASS Pathways
Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trialAll patients tolerated COMP360...
compass_positive_tagline-01.png
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
01 déc. 2021 07h00 HE | COMPASS Pathways
- Positive topline results validated by additional analyses - Patient improvements beyond reduction of depression symptoms - Further insights into timing and circumstance of adverse...
compass_positive_tagline-01.png
Guy Goodwin joins COMPASS Pathways as Chief Medical Officer
29 juil. 2021 08h30 HE | COMPASS Pathfinder Ltd.
COMPASS announces changes to its Executive Team London, UK – 29 July 2021         COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating...